RxBridge is a PBM designed especially for the Workers’ Compensation industry specializing in client-focused and flexible solutions for insurance companies, third party administrators, and self-insured employers to pharmacy networks and ensuring optimal processing efficiency through our proprietary world-class technologies.

Related News

INDUSTRY OUTLOOK

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

news image

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More

INDUSTRIAL IMPACT

ACTIVE MOTIF AND EPICYPHER EXECUTE CROSS-LICENSING AGREEMENT AND END ONGOING LITIGATION INVOLVING TARGETED TRANSPOSITION TECHNOLOGY FOR EPIGENOMICS

EpiCypher and Active Motif | August 01, 2022

news image

CUT&Tag is a targeted transposition technique that allows high-resolution genomic mapping of histone modifications and chromatin-associated proteins through the precise insertion of DNA sequences into the genome using the Tn5 transposase enzyme. EpiCypher and Active Motif each own or control patents covering complementary aspects of targeted transposition. Active Motif and EpiCypher have leveraged their respective IP to independently create successful genomic mapping tools tha...

Read More

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

INDUSTRIAL IMPACT

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

news image

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More
news image

INDUSTRY OUTLOOK

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More
news image

INDUSTRIAL IMPACT

ACTIVE MOTIF AND EPICYPHER EXECUTE CROSS-LICENSING AGREEMENT AND END ONGOING LITIGATION INVOLVING TARGETED TRANSPOSITION TECHNOLOGY FOR EPIGENOMICS

EpiCypher and Active Motif | August 01, 2022

CUT&Tag is a targeted transposition technique that allows high-resolution genomic mapping of histone modifications and chromatin-associated proteins through the precise insertion of DNA sequences into the genome using the Tn5 transposase enzyme. EpiCypher and Active Motif each own or control patents covering complementary aspects of targeted transposition. Active Motif and EpiCypher have leveraged their respective IP to independently create successful genomic mapping tools tha...

Read More
news image

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

INDUSTRIAL IMPACT

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More